Vanishing White Matter Disease
Vanishing White Matter disease (VWM) is a rare genetic disorder that affects the brain's white matter, leading to progressive neurological symptoms such as loss of motor skills, muscle stiffness, and cognitive decline.
Fosigotifator for Vanishing White Matter Disease
We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 6 months and 18 years old?
- Do you have VWM disease (a specific brain condition diagnosed by a doctor)?
- Are you currently pregnant, breastfeeding, or providing breast milk?
- Are you taking any medications for VWM disease symptoms that have changed in the last 4 weeks?
- Have you had any significant medical issues, like seizures, that are not well controlled in the last 6 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Abbv-cls-7262
Fosigotifator
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Amsterdam UMC
Pediatrics
Abcoude, Netherlands
Sponsor: AbbVie Deutschland GmbH & Co. KG
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.